Researchers showed that the novel contact lens, which uses strategically placed drug polymer film to deliver medication gradually to the eye, is possibly more effective than daily latanoprost eye drops in a pre-clinical model for glaucoma.
"We found that a lower-dose contact lens delivered the same amount of pressure reduction as the latanoprost drops, and a higher-dose lens, interestingly enough, had better pressure reduction than the drops in our small study," said Joseph B Ciolino, from the Harvard Medical School in the US.
Glaucoma is the leading cause of irreversible blindness in the world. While there is no cure for glaucoma, ocular medications aim to lower pressure in the eye with the goal of preventing vision loss.
Currently, the medications are delivered as eye drops, which sometimes cause stinging and burning, can be difficult to self-administer and are subsequently associated with poor patient compliance, with some studies suggesting that compliance is as low as 50 per cent.
Contact lenses have been studied as a means of ocular drug delivery for nearly 50 years, yet many such lenses are ineffective because they dispense the drug too quickly.
Researchers designed a novel contact lens that contains a thin film of drug-encapsulated polymers in the periphery. The drug-polymer film slows the drug coming out of the lens.
"Instead of taking a contact lens and allowing it to absorb a drug and release it quickly, our lens uses a polymer film to house the drug, and the film has a large ratio of surface area to volume, allowing the drug to release more slowly," said Daniel S Kohane, from the Boston Children's Hospital.
The effect of this drug eluting contact lens was assessed in four glaucomatous monkeys.
The researchers showed that the contact lens with lower doses of latanoprost delivers the same amount of eye pressure reduction as the eye drop version of the medication.
The study was published in the journal Ophthalmology.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
